KR20170033436A - 다낭성 신장병의 바이오마커 및 그의 용도 - Google Patents

다낭성 신장병의 바이오마커 및 그의 용도 Download PDF

Info

Publication number
KR20170033436A
KR20170033436A KR1020177005740A KR20177005740A KR20170033436A KR 20170033436 A KR20170033436 A KR 20170033436A KR 1020177005740 A KR1020177005740 A KR 1020177005740A KR 20177005740 A KR20177005740 A KR 20177005740A KR 20170033436 A KR20170033436 A KR 20170033436A
Authority
KR
South Korea
Prior art keywords
pkd
patient
cyclin
level
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177005740A
Other languages
English (en)
Korean (ko)
Inventor
옥사나 베스크로브나야
니콜라이 부카노브
사라 모레노
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Publication of KR20170033436A publication Critical patent/KR20170033436A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
KR1020177005740A 2014-08-04 2015-08-03 다낭성 신장병의 바이오마커 및 그의 용도 Withdrawn KR20170033436A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033031P 2014-08-04 2014-08-04
US62/033,031 2014-08-04
PCT/US2015/043497 WO2016022500A2 (en) 2014-08-04 2015-08-03 Biomarkers of polycystic kidney disease and uses thereof

Publications (1)

Publication Number Publication Date
KR20170033436A true KR20170033436A (ko) 2017-03-24

Family

ID=54035292

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005740A Withdrawn KR20170033436A (ko) 2014-08-04 2015-08-03 다낭성 신장병의 바이오마커 및 그의 용도

Country Status (12)

Country Link
US (1) US10871495B2 (enExample)
EP (1) EP3177932B1 (enExample)
JP (2) JP6730252B2 (enExample)
KR (1) KR20170033436A (enExample)
CN (1) CN106716136B (enExample)
AU (1) AU2015301278A1 (enExample)
BR (1) BR112017002003A2 (enExample)
CO (1) CO2017001596A2 (enExample)
MX (1) MX2017001648A (enExample)
RU (1) RU2017106891A (enExample)
SG (1) SG11201700290SA (enExample)
WO (1) WO2016022500A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210063203A (ko) * 2019-11-22 2021-06-01 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116755B2 (en) 2015-11-18 2021-09-14 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
GB201719520D0 (en) * 2017-11-24 2018-01-10 Univ College Cardiff Consultants Ltd Neuroprotectvie peptide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500418A (ja) * 1999-05-24 2003-01-07 エイブイアイ バイオファーマ， インコーポレイテッド 多発性嚢胞腎疾患の処置のためのｃ−ｍｙｃに対するアンチセンス
US9006181B2 (en) 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
US20120077263A1 (en) 2009-06-05 2012-03-29 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102018702B (zh) * 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
US20140079769A1 (en) * 2010-10-01 2014-03-20 Fabiola Terzi Methods for predicting the progression and treating a chronic kidney disease in a patient
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
ES2982997T3 (es) 2012-07-03 2024-10-21 Fond Centro San Raffaele 2-desoxiglucosa para uso en el tratamiento de la enfermedad renal poliquística dominante autosomal o enfermedad hepática poliquística
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210063203A (ko) * 2019-11-22 2021-06-01 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용

Also Published As

Publication number Publication date
EP3177932A2 (en) 2017-06-14
JP2020170013A (ja) 2020-10-15
RU2017106891A3 (enExample) 2019-03-14
RU2017106891A (ru) 2018-09-06
EP3177932B1 (en) 2021-07-14
JP6730252B2 (ja) 2020-07-29
JP7005695B2 (ja) 2022-02-04
CN106716136A (zh) 2017-05-24
BR112017002003A2 (pt) 2017-12-12
CN106716136B (zh) 2020-06-23
US20170227551A1 (en) 2017-08-10
MX2017001648A (es) 2017-04-27
US10871495B2 (en) 2020-12-22
CO2017001596A2 (es) 2017-05-19
WO2016022500A3 (en) 2016-04-07
SG11201700290SA (en) 2017-02-27
WO2016022500A2 (en) 2016-02-11
JP2017525955A (ja) 2017-09-07
AU2015301278A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
US12150938B2 (en) Biomarker of polycystic kidney disease and uses thereof
JP7005695B2 (ja) 多発性嚢胞腎のバイオマーカーおよびその使用
RU2720988C2 (ru) ИНГИБИТОРЫ GATA-3 ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ Th2-ИНДУЦИРОВАННОЙ АСТМЫ
García-Marchena et al. Psychiatric comorbidity and plasma levels of 2-acyl-glycerols in outpatient treatment alcohol users. Analysis of gender differences
Cains et al. Addressing a folate imbalance in fetal cerebrospinal fluid can decrease the incidence of congenital hydrocephalus
Spencer et al. Neuropathological profile of long‐duration amyotrophic lateral sclerosis in military veterans
JP5680744B2 (ja) 併用療法及び治療耐性評価方法
Wang et al. Lymphocyte α-kinase is a gout-susceptible gene involved in monosodium urate monohydrate-induced inflammatory responses
Li et al. The selective NADPH oxidase inhibitor apocynin has potential prophylactic effects on melamine-related nephrolithiasis in vitro and in vivo
JP2019502902A5 (enExample)
TW202112368A (zh) 用於治療有關dux4表現之疾病的抑制劑組合
Park et al. Regulation of phosphorylation of glycogen synthase kinase 3α and the correlation with sperm motility in human
Fiorina et al. 31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients
JP2017525955A5 (enExample)
Yongman et al. Renoprotective effect of benazepril on diabetic nephropathy mediated by P42/44MAPK
US20250339435A1 (en) Treatment of a selective population of patients having dementia with lewy bodies
WO2023172444A2 (en) Senotherapeutic agents and alpha-klotho polypeptides
Immanuel et al. IL-32 in limb-girdle muscular dystrophy LGMDR1-calpain 3 related: A Pilot Study on Its Role as a Biomarker
JP2024543228A (ja) 子宮内膜症の検出及び処置のための改善された方法
CN119492868A (zh) 一种系膜增生性肾小球肾炎的潜在生物标志物及其应用
HK1230980A1 (en) Gata-3 inhibitors for use in the treatment of th2-driven asthma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination